PHARMACOGENETICS / MEDICATION SAFETY / MVP 0.10
Check guideline scope. Never change treatment from a website.
The navigator answers one narrow question: is the selected gene–medicine–context relationship in our reviewed CPIC snapshot? If yes, it shows the primary source and questions for a clinician—but never turns a dosing table into personal advice.
priority gene–medicine pathways
including separate cardiac and neurovascular clopidogrel scenarios
doses, start/stop instructions or medicine rankings
CLINICAL BOUNDARY
Automate evidence retrieval—not the clinician’s decision.
CPIC explains how to use an already available pharmacogenetic result; it does not by itself decide whether a test should be ordered. A validated laboratory must explicitly report the phenotype: the site does not translate a variant or star allele into a metabolic phenotype.
Russian labels, the national register, medicine availability and local clinical guidance are not imported in this release. Selecting Russia stops the output. DPYD also requires a manual freshness check: CPIC has announced a pending update, so automated conversion of specific alleles is deliberately excluded.
All selected categories are matched only in browser memory against a local editorial set. They are not placed in the URL, cookies, storage, analytics, the controller’s server or an external API. Do not enter or send a name, diagnosis, test number, medicine list or report text.
The algorithm can only confirm that an exact relationship is in the limited CPIC set, report missing context or stop. It never outputs a dose, suggests a medicine or confirms that a medicine is safe for a particular person.
01 / WHAT IS CHECKED
A gene is only one layer of a medication decision.
- 01
Exact medicine
A relationship cannot be transferred to an entire class: the guideline is checked for an exact medicine and clinical question.
- 02
Reported phenotype
Star alleles, HLA and activity scores require assay coverage and a current translation table; the site fills in nothing.
- 03
Indication
Recommendation strength and clinical context can differ within one pair—for example, clopidogrel after PCI versus stroke/TIA.
- 04
Non-genetic factors
Concomitant medicines, liver and kidney function, pregnancy, age, current toxicity and treatment goals remain outside the algorithm.
02 / STOP RULES
An unclear result never becomes advice.
- VUS, genotype without phenotype or incomplete wording
- Consumer test or unknown allele coverage
- Child, pregnancy or breastfeeding
- Acute toxicity or a request to change treatment now
- Polypharmacy or severe kidney / liver impairment
- Medicine, gene, indication or local jurisdiction outside the set
03 / PRIMARY SOURCES
Evidence scales and versions stay separate.
Fluorouracil and capecitabine: translating a confirmed DPYD phenotype into clinical discussion.
↗CPIC / CYP2C192022 updateClopidogrel: distinct acute coronary syndrome/PCI and neurovascular contexts.
↗CPIC / HLA-B2014 updateAbacavir and HLA-B*57:01: guidance on hypersensitivity-reaction risk.
↗CPIC / TPMT + NUDT152025 update, accepted in 2026Azathioprine, mercaptopurine and thioguanine: combined TPMT and NUDT15 interpretation.
↗CPIC / SLCO1B12022 updateStatins and musculoskeletal-symptom risk; the first module is limited to simvastatin and SLCO1B1.
↗CPIC / DPYD STATUSofficial notice dated 9 July 2026Notice of the pending update and a specific change to the functional assessment of HapB3.
↗Editorial snapshot reviewed 30 August 2026. For DPYD, the public CPIC notice of 9 July 2026 about a pending update is acknowledged; no specific allele is translated into a recommendation here until the complete revision is published.
RELATED SECTIONS